Phase 2 Completed N=10 Randomized Quadruple-blind Treatment

Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation

Cardiac Arrest · Sudden cardiac arrest

Source: ClinicalTrials.gov NCT01319110 ↗

Enrolled (actual)

Serious AEs

40.0%

Results posted

Apr 2017

Primary outcomePrimary: Prevalence of Low Serum CoQ10 Levels in Cardiac Arrest Patients — 0.706; 0.66 ug/mL

Summary

Specific Aim #1: To determine if levels of CoQ10 are low post-cardiac arrest (CA). We will perform a prospective trial with the primary endpoint of describing the prevalence of low serum CoQ10 levels. Specific Aim #2: To determine if CoQ10 levels in post-CA patients can be increased with the administration of exogenous CoQ10.. We will perform a randomized control trial (RCT) of post-CA patients with the secondary endpoint of comparing CoQ10 levels among those randomized to CoQ10 supplementation vs placebo.

Outcome Measures

Outcome	Result	p-value
PRIMARY Prevalence of Low Serum CoQ10 Levels in Cardiac Arrest Patients	0.706; 0.66	—
SECONDARY Comparison of Serum CoQ10 Levels Randomized to Supplementation vs. Placebo	—	—

Eligibility Criteria

Inclusion Criteria

Adult patients (age > 18 years)
Comatose after CA with subsequent return of spontaneous circulation

Exclusion Criteria

Comatose status prior to CA
CoQ10 therapy within one month prior to CA
Pregnancy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01319110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.